biostudies-literatureGouraud HAgence Nationale de la RechercheAHRQ HHSFDA HHSNHLBI NIH HHSNIAAA NIH HHSe000154https://www.ebi.ac.uk/biostudies/studies/S-EPMC9978683biostudies-literatureUnknown1(1)<h4>Objective</h4>To evaluate the impact of conducting all possible pooled analyses across different combinations of randomised controlled trials and endpoints.<h4>Design</h4>Multiverse analysis, consisting of numerous pooled analyses of individual participant data.<h4>Setting</h4>Individual patient data from 12 randomised controlled trials comparing canagliflozin treatment with placebo, shared on the Yale University Open Data Access project (https://yoda.yale.edu/) platform, up to 16 April 2021.<h4>Participants</h4>15 094 people with type 2 diabetes mellitus.<h4>Main outcome measures</h4>Pooled analyses estimated changes in serum glycated haemoglobin (HbA1c), major adverse cardiovascular events, and serious adverse events at weeks 12, 18, 26, and 52. The distribution of effect estimates wBMJ medicineVibration of effect in more than 16 000 pooled analyses of individual participant data from 12 randomised controlled trials comparing canagliflozin and placebo for type 2 diabetes mellitus: multiverse analysis.PMC9978683R01 HL144644R01 HS025164ANR-17-CE-36-0010-01R01 HS022882U01 FD005938K01 AA028258Wallach JDBoussageon RNaudet FRoss JSGouraud HfalseVibration of effect in more than 16 000 pooled analyses of individual participant data from 12 randomised controlled trials comparing canagliflozin and placebo for type 2 diabetes mellitus: multiverse analysis.<h4>Objective</h4>To evaluate the impact of conducting all possible pooled analyses across different combinations of randomised controlled trials and endpoints.<h4>Design</h4>Multiverse analysis, consisting of numerous pooled analyses of individual participant data.<h4>Setting</h4>Individual patient data from 12 randomised controlled trials comparing canagliflozin treatment with placebo, shared on the Yale University Open Data Access project (https://yoda.yale.edu/) platform, up to 16 April 2021.<h4>Participants</h4>15 094 people with type 2 diabetes mellitus.<h4>Main outcome measures</h4>Pooled analyses estimated changes in serum glycated haemoglobin (HbA1c), major adverse cardiovascular events, and serious adverse events at weeks 12, 18, 26, and 52. The distribution of effect estimates w2022-01-01T00:00:00Z20222026-06-13T06:13:08.572Z2024-11-12T18:08:51.659ZS-EPMC99786833693656410.1136/bmjmed-2022-000154